These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9371946)

  • 21. Disturbed metabolism of guanidino compounds characterized by elevated excretion of beta-guanidinopropionic acid and gamma-guanidinobutyric acid--an effect of vigabatrin treatment?
    Schulze A; Mayatepek E; Frank S; Marescau B; De Deyn PP; Bachert P
    J Inherit Metab Dis; 1998 Jun; 21(3):268-71. PubMed ID: 9686372
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute pancreatitis associated with dual vigabatrin and lamotrigine therapy.
    Jadresic D
    Seizure; 1994 Dec; 3(4):319. PubMed ID: 7534594
    [No Abstract]   [Full Text] [Related]  

  • 23. Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril).
    Lambert MV; Bird JM
    Seizure; 1997 Jun; 6(3):233-5. PubMed ID: 9203253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Acute psychosis and vigabatrin in childhood].
    Chiaretti A; Castorina M; Tortorolo L; Piastra M; Polidori G
    Pediatr Med Chir; 1994; 16(5):489-90. PubMed ID: 7885961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe persistent visual field constriction associated with vigabatrin.
    Eke T; Talbot JF; Lawden MC
    BMJ; 1997 Jan; 314(7075):180-1. PubMed ID: 9022432
    [No Abstract]   [Full Text] [Related]  

  • 26. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.
    Mackenzie R; Klistorner A
    BMJ; 1998 Jan; 316(7126):233. PubMed ID: 9468717
    [No Abstract]   [Full Text] [Related]  

  • 27. Rapid aggravation of aphasia by vigabatrin.
    Gil R; Neau JP
    J Neurol; 1995 Mar; 242(4):251-2. PubMed ID: 7798126
    [No Abstract]   [Full Text] [Related]  

  • 28. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.
    Blackwell N; Hayllar J; Kelly G
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193313
    [No Abstract]   [Full Text] [Related]  

  • 29. Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy).
    Somerville ER
    Epilepsia; 2009 Sep; 50 Suppl 8():31-6. PubMed ID: 19702731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vigabatrin in unsatisfactory controlled epilepsies. Swiss Vigabatrin Study Group.
    Russ W
    Schweiz Arch Neurol Psychiatr (1985); 1995; 146(2):55-9. PubMed ID: 7569836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-epileptic drugs-induced de novo absence seizures.
    Yang MT; Lee WT; Chu LW; Shen YZ
    Brain Dev; 2003 Jan; 25(1):51-6. PubMed ID: 12536034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vigabatrin-induced optic neuropathy.
    Crofts K; Brennan R; Kearney P; O'Connor G
    J Neurol; 1997 Oct; 244(10):666-7. PubMed ID: 9402546
    [No Abstract]   [Full Text] [Related]  

  • 33. Vigabatrin edema.
    Cocito L; Maffini M
    Neurology; 1995 Nov; 45(11):2115-6. PubMed ID: 7501178
    [No Abstract]   [Full Text] [Related]  

  • 34. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.
    Wong IC; Mawer GE; Sander JW
    BMJ; 1997 Jun; 314(7095):1693-4. PubMed ID: 9193312
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical use of drugs useful in the treatment of atonic seizures.
    Bourgeois B
    Adv Neurol; 1995; 67():361-7. PubMed ID: 8848980
    [No Abstract]   [Full Text] [Related]  

  • 36. Perioral myoclonia with absences and myoclonic status aggravated by oxcarbazepine.
    Vrielynck P; Rostomashvili N; Degroote E; Ghariani S; van Rijckevorsel K
    Epileptic Disord; 2011 Sep; 13(3):308-12. PubMed ID: 21873142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of association between vigabatrin and impaired cognition.
    Monaco F; Torta R; Cicolin A; Borio R; Varetto A; Bergamasco L; Vighetti S
    J Int Med Res; 1997; 25(5):296-301. PubMed ID: 9364292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist.
    Harding GF
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193314
    [No Abstract]   [Full Text] [Related]  

  • 39. Guideline may help in prescribing vigabatrin.
    Appleton RE
    BMJ; 1998 Nov; 317(7168):1322. PubMed ID: 9804738
    [No Abstract]   [Full Text] [Related]  

  • 40. Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies.
    Backstrom JT; Hinkle RL; Flicker MR
    BMJ; 1997 Jun; 314(7095):1694-5. PubMed ID: 9193315
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.